title: Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
abstract: Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 genes, the products of which contribute to the conservative homologous recombination repair of DNA double-strand breaks. Nonetheless, several setbacks in clinical trial settings have highlighted some of the issues surrounding the investigation of PARP inhibitors, especially the identification of patients who stand to benefit from such drugs. One potential approach to finding this patient subpopulation is to examine the tumor DNA for evidence of a homologous recombination defect. However, although the genomes of many breast and ovarian cancers are replete with aberrations, the presence of numerous factors able to shape the genomic landscape means that only some of the observed DNA abnormalities are the outcome of a cancer cell's inability to faithfully repair DNA double-strand breaks. Consequently, recently developed methods for comprehensively capturing the diverse ways in which homologous recombination deficiencies may arise beyond BRCA1/2 mutation have used DNA microarray and sequencing data to account for potentially confounding features in the genome. Scores capturing telomeric allelic imbalance, loss of heterozygosity (LOH) and large scale transition score, as well as the total number of coding mutations are measures that summarize the total burden of certain forms of genomic abnormality. By contrast, other studies have comprehensively catalogued different types of mutational pattern and their relative contributions to a given tumor sample. Although at least one study to explore the use of the LOH scar in a prospective clinical trial of a PARP inhibitor in ovarian cancer is under way, limitations that result in a relatively low positive predictive value for these biomarkers remain. Tumors whose genome has undergone one or more events that restore high-fidelity homologous recombination are likely to be misclassified as double-strand break repair-deficient and thereby sensitive to PARP inhibitors and DNA damaging chemotherapies as a result of prior repair deficiency and its genomic scarring. Therefore, we propose that integration of a genomic scar-based biomarker with a marker of resistance in a high genomic scarring burden context may improve the performance of any companion diagnostic for PARP inhibitors.
authors.forename: Johnathan A
authors.initials: JA
authors.lastname: Watkins
authors.forename: Sheeba
authors.initials: S
authors.lastname: Irshad
authors.forename: Anita
authors.initials: A
authors.lastname: Grigoriadis
authors.forename: Andrew N J
authors.initials: AN
authors.lastname: Tutt
mesh_terms: D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy*; D002869:Chromosome Aberrations; D053903:DNA Breaks, Double-Stranded; D005260:Female; D059765:Homologous Recombination / Q000235:genetics; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D059767:Recombinational DNA Repair / Q000235:genetics*
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D014408:Biomarkers, Tumor; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
references.citation: J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
references.pmid: 10749912
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):130-5
references.pmid: 11136250
references.citation: Lancet. 2010 Jul 24;376(9737):235-44
references.pmid: 20609467
references.citation: N Engl J Med. 2009 Jul 9;361(2):123-34
references.pmid: 19553641
references.citation: Cell. 2011 Jan 7;144(1):27-40
references.pmid: 21215367
references.citation: Oncogene. 2001 Aug 2;20(34):4640-9
references.pmid: 11498787
references.citation: Clin Cancer Res. 2012 Oct 15;18(20):5806-15
references.pmid: 22912389
references.citation: Sci Signal. 2011 Mar 29;4(166):ra19
references.pmid: 21447800
references.citation: EMBO Mol Med. 2009 Sep;1(6-7):323-37
references.pmid: 20049736
references.citation: Cell. 2012 May 25;149(5):994-1007
references.pmid: 22608083
references.citation: Nat Genet. 2008 Jun;40(6):722-9
references.pmid: 18438408
references.citation: Clin Cancer Res. 2012 Mar 15;18(6):1655-62
references.pmid: 22291137
references.citation: Hum Genet. 2008 Aug;124(1):31-42
references.pmid: 18575892
references.citation: J Clin Oncol. 2011 Aug 1;29(22):3008-15
references.pmid: 21709188
references.citation: Nat Rev Cancer. 2006 Dec;6(12):924-35
references.pmid: 17109012
references.citation: Cell. 2012 May 25;149(5):979-93
references.pmid: 22608084
references.citation: Cancer Res. 2012 Nov 1;72(21):5454-62
references.pmid: 22933060
references.citation: Nature. 2011 Jun 29;474(7353):609-15
references.pmid: 21720365
references.citation: Nat Rev Clin Oncol. 2010 Dec;7(12):683-92
references.pmid: 20877296
references.citation: Nature. 2005 Apr 14;434(7035):917-21
references.pmid: 15829967
references.citation: Nat Genet. 2008 Jan;40(1):102-7
references.pmid: 18066063
references.citation: Cancer Discov. 2013 Jan;3(1):68-81
references.pmid: 23103855
references.citation: Br J Cancer. 2012 Nov 6;107(10):1776-82
references.pmid: 23047548
references.citation: Br J Cancer. 2007 Jan 15;96(1):11-5
references.pmid: 17213823
references.citation: Nature. 2005 Apr 14;434(7035):913-7
references.pmid: 15829966
references.citation: Oncogene. 2013 Aug 1;32(31):3577-86
references.pmid: 22926521
references.citation: Lancet Oncol. 2011 Sep;12(9):852-61
references.pmid: 21862407
references.citation: PLoS One. 2013 Nov 12;8(11):e80023
references.pmid: 24265793
references.citation: Ann Oncol. 2011 Jul;22(7):1561-1570
references.pmid: 21135055
references.citation: Trends Biochem Sci. 2012 Oct;37(10):418-24
references.pmid: 22836122
references.citation: Lancet. 2010 Jul 24;376(9737):245-51
references.pmid: 20609468
references.citation: Nature. 2008 Feb 28;451(7182):1111-5
references.pmid: 18264088
references.citation: Breast Cancer Res Treat. 2013 Jun;139(2):317-27
references.pmid: 23670131
references.citation: Mol Cell. 2011 Oct 21;44(2):235-51
references.pmid: 21963239
references.citation: EMBO Mol Med. 2010 Apr;2(4):130-42
references.pmid: 20373286
references.citation: Nat Rev Cancer. 2005 Sep;5(9):689-98
references.pmid: 16110319
references.citation: Cancer Discov. 2012 Apr;2(4):366-375
references.pmid: 22576213
references.citation: Cancer Res. 2008 Apr 15;68(8):2581-6
references.pmid: 18413725
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
references.pmid: 18971340
references.citation: Nat Rev Cancer. 2004 Oct;4(10):814-9
references.pmid: 15510162
references.citation: Breast. 2011 Oct;20 Suppl 3:S12-9
references.pmid: 22015278
references.citation: Oncogene. 2007 Mar 29;26(14):2126-32
references.pmid: 17016441
references.citation: Nature. 2013 Aug 22;500(7463):415-21
references.pmid: 23945592
references.citation: Drug Resist Updat. 2011 Feb;14(1):22-34
references.pmid: 21251871
references.citation: Trends Genet. 2008 Feb;24(2):64-9
references.pmid: 18192061
references.citation: Clin Cancer Res. 2013 Dec 1;19(23):6380-8
references.pmid: 24298068
references.citation: Nature. 2008 Feb 28;451(7182):1116-20
references.pmid: 18264087
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47
references.pmid: 22144499
references.citation: Ann Oncol. 2011 Apr;22(4):870-876
references.pmid: 20937646
references.citation: Lancet Oncol. 2013 Aug;14(9):882-92
references.pmid: 23810788
references.citation: Nature. 2012 Jan 18;481(7381):306-13
references.pmid: 22258609